FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 29 filers reported holding FUSION PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,119,202 | -44.3% | 3,122,770 | 0.0% | 0.17% | -34.8% |
Q2 2023 | $14,583,336 | +23.9% | 3,122,770 | 0.0% | 0.26% | +14.3% |
Q1 2023 | $11,772,843 | +15.9% | 3,122,770 | -3.2% | 0.23% | +19.1% |
Q4 2022 | $10,158,026 | +4.6% | 3,224,770 | 0.0% | 0.19% | +7.8% |
Q3 2022 | $9,707,000 | +20.9% | 3,224,770 | 0.0% | 0.18% | +23.3% |
Q2 2022 | $8,030,000 | -68.0% | 3,224,770 | 0.0% | 0.15% | -64.0% |
Q1 2022 | $25,056,000 | +86.3% | 3,224,770 | 0.0% | 0.41% | +134.7% |
Q4 2021 | $13,447,000 | -47.3% | 3,224,770 | 0.0% | 0.17% | -38.4% |
Q3 2021 | $25,540,000 | -2.0% | 3,224,770 | 0.0% | 0.28% | +6.4% |
Q2 2021 | $26,056,000 | -24.6% | 3,224,770 | 0.0% | 0.26% | -18.3% |
Q1 2021 | $34,570,000 | -8.8% | 3,224,770 | 0.0% | 0.32% | -2.7% |
Q4 2020 | $37,891,000 | -2.2% | 3,224,770 | 0.0% | 0.33% | -31.8% |
Q3 2020 | $38,762,000 | -31.2% | 3,224,770 | 0.0% | 0.49% | -38.6% |
Q2 2020 | $56,337,000 | – | 3,224,770 | – | 0.79% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,670,516 | $11,562 | 3.36% |
ADAMS STREET PARTNERS LLC | 2,947,809 | $9,285,598 | 3.10% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,560,984 | $4,917,100 | 2.14% |
Sio Capital Management, LLC | 260,448 | $820,411 | 0.30% |
BRAIDWELL LP | 2,000,000 | $6,300,000 | 0.21% |
Orbimed Advisors | 3,224,770 | $10,158,026 | 0.19% |
TPG GP A, LLC | 2,551,794 | $8,038,151 | 0.16% |
Artal Group S.A. | 750,000 | $2,363 | 0.13% |
RA Capital Management | 659,992 | $2,078,975 | 0.04% |
SECTORAL ASSET MANAGEMENT INC | 57,297 | $180,486 | 0.04% |